(-0.02%) 5 307.05 points
(-0.04%) 39 790 points
(-0.08%) 16 781 points
(-0.93%) $79.06
(-1.96%) $2.70
(-0.46%) $2 427.30
(-1.04%) $32.09
(-0.17%) $1 061.90
(0.12%) $0.922
(-0.22%) $10.67
(0.03%) $0.787
(-0.35%) $90.36
0.31% $ 12.88
Live Chart Being Loaded With Signals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...
Stats | |
---|---|
Volumen de hoy | 6 755.00 |
Volumen promedio | 130 072 |
Capitalización de mercado | 89.20M |
EPS | $0 ( 2024-05-14 ) |
Próxima fecha de ganancias | ( $-0.770 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0400 |
ATR14 | $0.0850 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Amoroso Michael | Buy | 8 334 | Common Stock |
2024-05-08 | Kelly John Alexander | Buy | 8 334 | Common Stock |
2024-05-08 | Smith J. Jefferson | Buy | 833 | Common Stock |
2024-05-08 | Scimeca Dario | Buy | 833 | Common Stock |
2024-05-04 | Pire Shari Lisa | Buy | 4 202 | Common Stock |
INSIDER POWER |
---|
14.40 |
Last 100 transactions |
Buy: 2 573 781 | Sell: 1 742 339 |
Volumen Correlación
Precision BioSciences Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Precision BioSciences Inc Correlación - Moneda/Commodity
Precision BioSciences Inc Finanzas
Annual | 2023 |
Ingresos: | $48.73M |
Beneficio Bruto: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2023 |
Ingresos: | $48.73M |
Beneficio Bruto: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2022 |
Ingresos: | $25.10M |
Beneficio Bruto: | $16.09M (64.12 %) |
EPS: | $-41.95 |
FY | 2021 |
Ingresos: | $115.53M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico